These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 16040383)
1. Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility. Davis-Sproul JM; Harris MP; Davidson NE; Kobrin BJ; Jaffee EM; Emens LA Cytotherapy; 2005; 7(1):46-56. PubMed ID: 16040383 [TBL] [Abstract][Full Text] [Related]
2. Prolongation of the survival of breast cancer-bearing mice immunized with GM-CSF-secreting syngeneic/allogeneic fibroblasts transfected with a cDNA expression library from breast cancer cells. Kim TS; Jung MY; Cho D; Cohen EP Vaccine; 2006 Oct; 24(42-43):6564-73. PubMed ID: 16837111 [TBL] [Abstract][Full Text] [Related]
3. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962 [TBL] [Abstract][Full Text] [Related]
4. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Jaffee EM; Schutte M; Gossett J; Morsberger LA; Adler AJ; Thomas M; Greten TF; Hruban RH; Yeo CJ; Griffin CA Cancer J Sci Am; 1998; 4(3):194-203. PubMed ID: 9612602 [TBL] [Abstract][Full Text] [Related]
5. Highly successful therapeutic vaccinations combining dendritic cells and tumor cells secreting granulocyte macrophage colony-stimulating factor. Driessens G; Hamdane M; Cool V; Velu T; Bruyns C Cancer Res; 2004 Nov; 64(22):8435-42. PubMed ID: 15548715 [TBL] [Abstract][Full Text] [Related]
6. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257 [TBL] [Abstract][Full Text] [Related]
7. [The plasma levels of granulocyte-colony stimulating factor and granulocyte-macrophage colony stimulating factor in breast cancer patients]. Ławicki S; Czygier M; Omyła J; Bedkowska E; Szmitkowski M Pol Merkur Lekarski; 2007 Oct; 23(136):259-63. PubMed ID: 18293847 [TBL] [Abstract][Full Text] [Related]
8. Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma. Ohashi K; Kobayashi G; Fang S; Zhu X; Antonia SJ; Krieg AM; Sandler AD J Pediatr Surg; 2006 Aug; 41(8):1361-8. PubMed ID: 16863838 [TBL] [Abstract][Full Text] [Related]
9. Effective anti-tumor responses induced by recombinant bacillus Calmette-Guérin vaccines based on different tandem repeats of MUC1 and GM-CSF. Yuan S; Shi C; Han W; Ling R; Li N; Wang T Eur J Cancer Prev; 2009 Sep; 18(5):416-23. PubMed ID: 19550341 [TBL] [Abstract][Full Text] [Related]
10. Closing the manufacturing process of dendritic cell vaccines transduced with adenovirus vectors. Gulen D; Abe F; Maas S; Reed E; Cowan K; Pirruccello S; Wisecarver J; Warkentin P; Northam M; Turken O; Coskun U; Senesac J; Talmadge JE Int Immunopharmacol; 2008 Dec; 8(13-14):1728-36. PubMed ID: 18793758 [TBL] [Abstract][Full Text] [Related]
11. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Holmes JP; Gates JD; Benavides LC; Hueman MT; Carmichael MG; Patil R; Craig D; Mittendorf EA; Stojadinovic A; Ponniah S; Peoples GE Cancer; 2008 Oct; 113(7):1666-75. PubMed ID: 18726994 [TBL] [Abstract][Full Text] [Related]
12. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Janke M; Peeters B; de Leeuw O; Moorman R; Arnold A; Fournier P; Schirrmacher V Gene Ther; 2007 Dec; 14(23):1639-49. PubMed ID: 17914407 [TBL] [Abstract][Full Text] [Related]
13. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Higano CS; Corman JM; Smith DC; Centeno AS; Steidle CP; Gittleman M; Simons JW; Sacks N; Aimi J; Small EJ Cancer; 2008 Sep; 113(5):975-84. PubMed ID: 18646045 [TBL] [Abstract][Full Text] [Related]
14. Induction of anti-tumor immunity by lyophilized myeloma cells secreting GM-CSF. Wu S; Yuan D; Liu JN; Tan XY Oncol Rep; 2007 Jan; 17(1):129-33. PubMed ID: 17143489 [TBL] [Abstract][Full Text] [Related]
15. Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on lung cancer: roles of cyclooxygenase-2. Uemura Y; Kobayashi M; Nakata H; Kubota T; Saito T; Bandobashi K; Taguchi H Oncol Rep; 2007 Apr; 17(4):955-61. PubMed ID: 17342342 [TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902 [TBL] [Abstract][Full Text] [Related]
17. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma. Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012 [TBL] [Abstract][Full Text] [Related]
18. Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside. Lin JM; Li B; Rimmer E; VanRoey M; Jooss K Exp Hematol; 2008 Mar; 36(3):319-28. PubMed ID: 18279719 [TBL] [Abstract][Full Text] [Related]
19. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. Gutschalk CM; Herold-Mende CC; Fusenig NE; Mueller MM Cancer Res; 2006 Aug; 66(16):8026-36. PubMed ID: 16912178 [TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of DISC-GMCSF for the treatment of breast carcinoma. Loudon PT; McLean CS; Martin G; Curry J; Leigh Shaw M; Hoogstraten C; Verdegaal E; Osanto S J Gene Med; 2003 May; 5(5):407-16. PubMed ID: 12731089 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]